Article
Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes.
Journal of the American Heart Association - 21 Oct 2025
Losa Mattia, Ramusino Matteo Cotta, Cama Isabella, Gualco Lorenzo, Gandoglia Ilaria, Massa Federico, Donniaquio Andrea, Mortola Pierumberto, Argenti Lucia, Lombardo Lorenzo, Kreshpa Wendy, Pelagotti Virginia, Bozzo Giulia, Orso Beatrice, Mattioli Pietro, Arnaldi Dario, Cirone Alessio, Ali Shahzad, Hamedani Mehrnaz, Pulze Martina, Plantone Domenico, Lorenzini Luigi, Falcitano Laura, Mazzacane Federico, Perini Giulia, Costa Alfredo, Piana Michele, Castellan Lucio, Uccelli Antonio, Schenone Angelo, Kozberg Mariel, Piazza Fabrizio, Del Sette Massimo, Garbarino Sara, Roccatagliata Luca, Farina Lisa Maria, Pardini Matteo
Abstract excerpt
BACKGROUND: Cerebral amyloid angiopathy (CAA) is a heterogeneous small vessel disease that can occur independently or alongside Alzheimer disease (AD). CAA is diagnosed using the Boston Criteria 2.0, integrating clinical and neuroimaging features, whereas the Cerebrospinal Fluid (CSF) role in clinical practice remains under investigation. This study explores whether CSF biomarkers can identify distinct disease...
Read the complete abstract on PubMedTopics
- Humans
- Cerebral Amyloid Angiopathy